Shanghai Haohai Biological Technology Co., Ltd.

SEHK:6826 Stock Report

Market Cap: HK$14.2b

Shanghai Haohai Biological Technology Management

Management criteria checks 4/4

Shanghai Haohai Biological Technology's CEO is Jianying Wu, appointed in Jul 2010, has a tenure of 14.42 years. directly owns 3.69% of the company’s shares, worth HK$523.35M. The average tenure of the management team and the board of directors is 10 years and 11.1 years respectively.

Key information

Jianying Wu

Chief executive officer

CN¥1.9m

Total compensation

CEO salary percentagen/a
CEO tenure14.4yrs
CEO ownership3.7%
Management average tenure10yrs
Board average tenure11.1yrs

Recent management updates

Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All

May 22
Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All

Recent updates

We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease

Jul 25
We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease

Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All

May 22
Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All

Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Apr 17
Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?

Feb 12
Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?

Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Nov 14
Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

Jul 28
Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt

Mar 09
We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt

These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well

Nov 25
These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well

Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

Jul 30
Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price

May 08
Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price

Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Apr 19
Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)

Mar 04
Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)

Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Mar 03
Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Is Shanghai Haohai Biological Technology (HKG:6826) A Risky Investment?

Jan 10
Is Shanghai Haohai Biological Technology (HKG:6826) A Risky Investment?

Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Oct 08
Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Here's Why Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt Responsibly

Jul 07
Here's Why Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt Responsibly

Analysts Have Just Cut Their Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Revenue Estimates By 14%

May 27
Analysts Have Just Cut Their Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Revenue Estimates By 14%

These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well

Apr 04
These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well

Investors Who Bought Shanghai Haohai Biological Technology (HKG:6826) Shares A Year Ago Are Now Up 58%

Mar 16
Investors Who Bought Shanghai Haohai Biological Technology (HKG:6826) Shares A Year Ago Are Now Up 58%

CEO Compensation Analysis

How has Jianying Wu's remuneration changed compared to Shanghai Haohai Biological Technology's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

CN¥430m

Jun 30 2024n/an/a

CN¥446m

Mar 31 2024n/an/a

CN¥432m

Dec 31 2023CN¥2mn/a

CN¥416m

Sep 30 2023n/an/a

CN¥346m

Jun 30 2023n/an/a

CN¥315m

Mar 31 2023n/an/a

CN¥226m

Dec 31 2022CN¥2mCN¥855k

CN¥180m

Sep 30 2022n/an/a

CN¥203m

Jun 30 2022n/an/a

CN¥192m

Mar 31 2022n/an/a

CN¥272m

Dec 31 2021CN¥1mCN¥845k

CN¥352m

Sep 30 2021n/an/a

CN¥428m

Jun 30 2021n/an/a

CN¥434m

Mar 31 2021n/an/a

CN¥370m

Dec 31 2020CN¥1mCN¥768k

CN¥230m

Sep 30 2020n/an/a

CN¥232m

Jun 30 2020n/an/a

CN¥216m

Mar 31 2020n/an/a

CN¥279m

Dec 31 2019CN¥2mCN¥742k

CN¥371m

Sep 30 2019n/an/a

CN¥353m

Jun 30 2019n/an/a

CN¥386m

Mar 31 2019n/an/a

CN¥375m

Dec 31 2018CN¥1mCN¥712k

CN¥415m

Sep 30 2018n/an/a

CN¥411m

Jun 30 2018n/an/a

CN¥408m

Mar 31 2018n/an/a

CN¥390m

Dec 31 2017CN¥1mCN¥583k

CN¥372m

Compensation vs Market: Jianying's total compensation ($USD261.64K) is below average for companies of similar size in the Hong Kong market ($USD561.88K).

Compensation vs Earnings: Jianying's compensation has been consistent with company performance over the past year.


CEO

Jianying Wu (60 yo)

14.4yrs

Tenure

CN¥1,904,800

Compensation

Dr. Jianying Wu has been General Manager of Shanghai Haohai Biological Technology Co., Ltd. since July 23, 2010 and has been its Executive Director since December 2014. Mr. Wu served as a Director at Shang...


Leadership Team

NamePositionTenureCompensationOwnership
Yongtai Hou
Executive Chairman14.4yrsCN¥1.89m3.65%
HK$ 518.0m
Jianying Wu
GM & Executive Director14.4yrsCN¥1.90m3.69%
HK$ 523.4m
Minjie Tang
CFO & Executive Director8yrsCN¥1.45m0.036%
HK$ 5.2m
Yiyi Chen
Executive Director10yrsCN¥1.26m0.26%
HK$ 36.6m
Min Tian
Joint Company Secretary5yrsCN¥868.70k0.0044%
HK$ 627.4k
Caixia Ren
Deputy General Manager10.3yrsCN¥912.50k0.012%
HK$ 1.7m
Ming King Chiu
Joint Company Secretary10.1yrsno datano data

10.0yrs

Average Tenure

49yo

Average Age

Experienced Management: 6826's management team is seasoned and experienced (10 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Yongtai Hou
Executive Chairman14.4yrsCN¥1.89m3.65%
HK$ 518.0m
Jianying Wu
GM & Executive Director14.4yrsCN¥1.90m3.69%
HK$ 523.4m
Minjie Tang
CFO & Executive Director7.8yrsCN¥1.45m0.036%
HK$ 5.2m
Yiyi Chen
Executive Director14.4yrsCN¥1.26m0.26%
HK$ 36.6m
Hongbo Shen
Independent Non-Executive Directorless than a yearno datano data
Jie You
Non Executive Director14.4yrsno data47.38%
HK$ 6.7b
Ming Ping Huang
Non-Executive Director14.4yrsCN¥150.00k1.22%
HK$ 172.5m
Yuanzhong Liu
Chairman of the Supervisory Committee14.4yrsno data1.22%
HK$ 172.5m
Lei Zhao
Independent Non-Executive Director4.5yrsCN¥150.00kno data
Zhi Su
Independent Non-Executive Director4.5yrsCN¥150.00kno data
Zhihong Jiang
Independent Non-Executive Director4.5yrsCN¥150.00kno data
Yushe Yang
Independent Non-Executive Director4.5yrsCN¥150.00kno data

11.1yrs

Average Tenure

52.5yo

Average Age

Experienced Board: 6826's board of directors are seasoned and experienced ( 11.1 years average tenure).